Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
121 hedge funds and large institutions have $383M invested in Progenics Pharmaceuticals Inc in 2015 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 45 reducing their positions, and 24 closing their positions.
44% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $706K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less capital invested
Capital invested by funds: $386M → $383M (-$3.32M)
9% less funds holding
Funds holding: 133 → 121 (-12)
16% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 45
50% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$2.69M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$2.19M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$1.9M |
| 4 |
AI
Analytic Investors
Los Angeles,
California
|
+$859K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$774K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$14.1M |
| 2 |
RA
Royce & Associates
New York
|
-$4.57M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$4.52M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.97M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$2.53M |
PGNX Hedge Fund Activity: Q4 2015 in Review
121 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2015, worth a combined $383M — down 0.86% from $386M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of PGNX and 12 opened new positions — a net loss of 12 holders — while 45 trimmed existing stakes and 38 added.
The largest buyer was Rice Hall James & Associates, adding an estimated $2.69M. The largest seller was State Street, cutting an estimated $14.1M.
- 121 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2015, down from 133 in Q3 2015.
- Funds reported $383M of Progenics Pharmaceuticals Inc stock for Q4 2015, down 0.86% quarter-over-quarter.
- 12 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2015 and 24 closed out, a net change of -12 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q4 2015 was Rice Hall James & Associates, an estimated $2.69M added.
- The largest Progenics Pharmaceuticals Inc seller in Q4 2015 was State Street, an estimated $14.1M sold.
Based on aggregated 13F filings for Q4 2015.